Previous 10 | Next 10 |
NEW HAVEN, Conn., March 30, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics Company Precipio, Inc. (NASDAQ: PRPO) , announced its audited results for 2020. The Company posted revenues of $6.1 million, an increase of $3.0 million from 2019, representing a 95% year-over-year in...
NEW HAVEN, Conn., March 18, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q4-2020 and year end corporate update call on Wednesday, March 31 st at 5:00 PM ET. The call will include updates on all of the company...
NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that Mr. Ron Andrews has joined the company’s Board of Directors. As the company continues to build its products division around comme...
Precipio ([[PRPO]] +1.6%) appoints Richard Sandberg as its board chairman, succeeding Douglas Fisher who will continue in the role of director.Sandberg has been involved with Precipio since its inception and joined its board in 2019, contributing through strategy form...
NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his rol...
Are Biotech Penny Stocks Part Of Your Strategy In 2021? It’s February 2021, and the markets are at all-time highs. Trading volumes remain strong, and penny stocks continue captivating retail traders. We also see several hot industries fanning the flames of this market rally. ...
Precipio ([[PRPO]] -6.6%) has begun to roll out Nirmidas Biotech's COVID-19 antibody tests following receipt of an Emergency Use Authorization from the FDA.The test, produced by Nirmidas, a biotech company based in Palo Alto, CA is the first U...
NEW HAVEN, Conn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that following receipt of an Emergency Use Authorization from the FDA by Nirmidas Biotech, Inc., the developer and manufacturer of...
Helius Medical Technologies (HSDT) -17%.Avinger (AVGR) -12%.Cango (CANG) -11%.OncoCyte (OCX) -10%.Obalon Therapeutics (OBLN) -10%.Dolphin Entertainment (DLPN) -9%.Surgalign Holdings (SRGA) -8% after pricing equity offering at $1.50.Vertex Energy (VTNR) -7%.Atossa Therapeutics (ATOS)...
Precipio (PRPO) has signed agreements with two of the largest oncology practices in the US for the use of its Reagent Rental Program HemeScreen.During the coming weeks, both practices, West Cancer Center of Memphis and New York Cancer & Blood Speci...
News, Short Squeeze, Breakout and More Instantly...
NEW HAVEN, Conn., July 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was $0.3M of cash generated for the quarter. It is important to not...
NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Patholog...
NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that the company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) was convened and adjourned, without any business being conducted...